ArticleACS omega2026
Chitosan-Gum Arabic Coated Nanostructured Lipid Carriers for Enhanced Gastrointestinal Stability of Curcuminoids.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcuminoids possess potent anti-inflammatory and antioxidant properties but suffer from poor aqueous solubility and rapid gastric degradation, limiting their therapeutic efficacy. This study developed turmeric curcuminoid-loaded nanostructured lipid carriers (TUR-NLCs) with chitosan-gum Arabic (CS-GA) polyelectrolyte complex coatings to enhance gastrointestinal stability and controlled oral delivery. TUR-NLCs were prepared via hot emulsification-microfluidization using optimized medium-chain triglyceride (MCT) and glycerol monostearate (GMS) ratios, followed by coating with a preformed CS-GA polyelectrolyte complex. The nanocarriers were comprehensively characterized for physicochemical properties, drug release kinetics, gastrointestinal stability, and biological activity. The optimized formulation (6MCT/3GMS) achieved a particle size of 53.20 ± 2.1 nm with 68.04 ± 0.98% encapsulation efficiency. Solid-state characterization indicated an amorphous or noncrystalline state of curcuminoids within the lipid matrix. The CS-GA coating significantly enhanced stability under simulated gastric conditions (pH 1.2), with controlled intestinal release following Fickian diffusion mechanisms (Korsmeyer-Peppas model,
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.